PL3596123T3 - Anty-cd25 zoptymalizowane pod względem fc do specyficznego zmniejszania liczby komórek nowotworu - Google Patents

Anty-cd25 zoptymalizowane pod względem fc do specyficznego zmniejszania liczby komórek nowotworu

Info

Publication number
PL3596123T3
PL3596123T3 PL18711313.9T PL18711313T PL3596123T3 PL 3596123 T3 PL3596123 T3 PL 3596123T3 PL 18711313 T PL18711313 T PL 18711313T PL 3596123 T3 PL3596123 T3 PL 3596123T3
Authority
PL
Poland
Prior art keywords
specific cell
cell depletion
tumour specific
optimized anti
optimized
Prior art date
Application number
PL18711313.9T
Other languages
English (en)
Inventor
Anne Goubier
Pascal Merchiers
Josephine SALIMU
Beatriz GOYENECHEA CORZO
Kevin Moulder
Sergio Quezada
Karl PEGGS
Frederick ARCE VARGAS
Isabelle SOLOMON
Original Assignee
Tusk Therapeutics Ltd
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3596123(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1710879.6A external-priority patent/GB201710879D0/en
Priority claimed from GBGB1714429.6A external-priority patent/GB201714429D0/en
Application filed by Tusk Therapeutics Ltd, Cancer Research Technology Limited filed Critical Tusk Therapeutics Ltd
Publication of PL3596123T3 publication Critical patent/PL3596123T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18711313.9T 2017-03-17 2018-03-13 Anty-cd25 zoptymalizowane pod względem fc do specyficznego zmniejszania liczby komórek nowotworu PL3596123T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17161717 2017-03-17
GBGB1710879.6A GB201710879D0 (en) 2017-07-06 2017-07-06 Methods and compounds for tumour-specific cell depletion
GBGB1714429.6A GB201714429D0 (en) 2017-09-07 2017-09-07 Compounds and methods for tumour-specific cell depletion
PCT/EP2018/056312 WO2018167104A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion

Publications (1)

Publication Number Publication Date
PL3596123T3 true PL3596123T3 (pl) 2024-06-24

Family

ID=61655786

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18711313.9T PL3596123T3 (pl) 2017-03-17 2018-03-13 Anty-cd25 zoptymalizowane pod względem fc do specyficznego zmniejszania liczby komórek nowotworu

Country Status (26)

Country Link
US (1) US11879014B2 (pl)
EP (1) EP3596123B1 (pl)
JP (2) JP2020514363A (pl)
KR (1) KR20190130137A (pl)
CN (1) CN110869388B (pl)
AU (1) AU2018233976B2 (pl)
BR (1) BR112019017017A2 (pl)
CA (1) CA3056506A1 (pl)
CL (1) CL2019002624A1 (pl)
CR (1) CR20190477A (pl)
DK (1) DK3596123T3 (pl)
ES (1) ES2975063T3 (pl)
FI (1) FI3596123T3 (pl)
HR (1) HRP20240469T1 (pl)
HU (1) HUE065999T2 (pl)
IL (1) IL269081B1 (pl)
LT (1) LT3596123T (pl)
MX (1) MX2019010974A (pl)
MY (1) MY208220A (pl)
PE (1) PE20191812A1 (pl)
PL (1) PL3596123T3 (pl)
RS (1) RS65351B1 (pl)
SG (1) SG11201908578YA (pl)
SI (1) SI3596123T1 (pl)
WO (1) WO2018167104A1 (pl)
ZA (1) ZA201904980B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
EP3880227A4 (en) 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. ANTI-CD25 ANTIBODIES
EP3880698A4 (en) 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
EP3972997A1 (en) * 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Novel anti-cd25 antibodies
JP7245358B2 (ja) * 2019-06-10 2023-03-23 山東博安生物技術股▲ふん▼有限公司 抗ｃｄ２５抗体及びその適用
WO2021207691A1 (en) 2020-04-10 2021-10-14 Rakuten Medical, Inc. Phthalocyanine dye compounds, conjugates and methods of use thereof
JP2023525060A (ja) * 2020-05-14 2023-06-14 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ２５抗体、その抗原結合断片及びその医薬用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
JP2024504547A (ja) * 2020-11-20 2024-02-01 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 抗ｃｄ２５抗体
EP4247497A1 (en) * 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
JP2024505556A (ja) * 2021-02-02 2024-02-06 ラクテン・メディカル，インコーポレイテッド がん、腫瘍および腫瘍細胞の局所および全身処置のための方法
KR20230154012A (ko) 2021-03-01 2023-11-07 에프. 호프만-라 로슈 아게 신규 바이오마커 및 이의 용도
US20240352136A1 (en) 2021-09-02 2024-10-24 Hoffmann-La Roche Inc. Antibodies for the treatment of aml
EP4514388A1 (en) 2022-04-26 2025-03-05 F. Hoffmann-La Roche AG Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist
CN115181182B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种人源化的抗cd25的单域抗体及其应用
EP4547274A1 (en) * 2022-06-30 2025-05-07 The United States of America, as represented by the Secretary, Department of Health and Human Services Cd25-specific antibodies and uses thereof
CN119451978A (zh) 2022-07-01 2025-02-14 神经基因治疗公司 Neo-2/15变体及其用于优先刺激T调节细胞的用途
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN118240080A (zh) * 2022-12-22 2024-06-25 深圳市福元生物科技有限公司 一种cd25单域抗体、人源化抗体、及制备方法
WO2024165454A1 (en) 2023-02-06 2024-08-15 F. Hoffmann-La Roche Ag Combination therapy and uses thereof
CN116087499B (zh) * 2023-02-20 2023-10-31 深圳裕康医学检验实验室 一种癌样本的染色方法及试剂盒
CN120314588B (zh) * 2025-05-21 2025-10-17 成都蓉生药业有限责任公司 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
GB0409799D0 (en) * 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
AR064801A1 (es) 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
RU2391401C2 (ru) 2008-02-12 2010-06-10 Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
CA2784953C (en) * 2009-12-21 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
EP2595657A4 (en) 2010-07-22 2015-09-23 Univ California ANTI-TUMOR ANTIGEN ANTIBODIES AND USE PROCESSES
EP2970486B1 (en) * 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
MX2015012563A (es) 2013-03-15 2016-10-26 Abbvie Biotechnology Ltd Anticuerpos anti-cd25 y sus usos.
HK1220470A1 (zh) 2013-03-15 2017-05-05 Abbvie Biotechnology Ltd. 抗cd25抗体及其用途
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20190017735A (ko) 2016-04-07 2019-02-20 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
UA129536C2 (uk) 2018-03-13 2025-05-28 Туск Терап'Ютікс Лтд Анти-cd25 для виснаження пухлиноспецифічних клітин

Also Published As

Publication number Publication date
HUE065999T2 (hu) 2024-06-28
CN110869388B (zh) 2024-09-20
HRP20240469T1 (hr) 2024-07-19
CR20190477A (es) 2020-01-07
SI3596123T1 (sl) 2024-05-31
MX2019010974A (es) 2020-08-03
PE20191812A1 (es) 2019-12-26
ES2975063T3 (es) 2024-07-03
US20200010554A1 (en) 2020-01-09
CN110869388A (zh) 2020-03-06
WO2018167104A1 (en) 2018-09-20
EP3596123B1 (en) 2024-01-10
NZ756984A (en) 2025-08-29
LT3596123T (lt) 2024-03-25
IL269081B1 (en) 2026-01-01
ZA201904980B (en) 2026-03-25
DK3596123T3 (da) 2024-02-26
KR20190130137A (ko) 2019-11-21
AU2018233976A1 (en) 2019-10-31
CA3056506A1 (en) 2018-09-20
BR112019017017A2 (pt) 2020-04-14
IL269081A (en) 2019-11-28
US11879014B2 (en) 2024-01-23
AU2018233976B2 (en) 2025-03-20
JP2020514363A (ja) 2020-05-21
RS65351B1 (sr) 2024-04-30
CL2019002624A1 (es) 2020-04-03
JP2024050684A (ja) 2024-04-10
MY208220A (en) 2025-04-24
EP3596123A1 (en) 2020-01-22
SG11201908578YA (en) 2019-10-30
FI3596123T3 (fi) 2024-04-17

Similar Documents

Publication Publication Date Title
SG11202008733YA (en) Anti-cd25 for tumour specific cell depletion
HUE065999T2 (hu) Fc-optimalizált anti-CD25 tumorspecifikus sejtdeplécióhoz
IL255884A (en) Modified nk-92 cells for cancer treatment
IL273915A (en) cell
GB201611982D0 (en) Cell culture
GB201610515D0 (en) Cell
GB201621889D0 (en) Cell
GB201713078D0 (en) T Cell Modification
IL278204A (en) Anti-BCMA CAR-T cells to deplete plasma cells
GB201714718D0 (en) Cell
GB201616238D0 (en) Modified T cells
GB201603372D0 (en) Cell
GB201707779D0 (en) Cell
GB201720949D0 (en) Cell
GB201803079D0 (en) Cell
SG11202005559VA (en) Improved cell culture device
GB201707783D0 (en) Cell
IL264169A (en) B-cell-mimetic cells
GB201609604D0 (en) Cell
GB201718697D0 (en) Cell
PL3287521T3 (pl) Hodowla komórkowa
GB201617716D0 (en) Cell
IL276997A (en) Anti-CD25 to deplete specific cells of yours
IL252570A0 (en) in the colon of a small cell
PT3596123T (pt) Anti-cd25 optimizado em termos de fc para depleção de células específicas a tumores